Business Standard

Sanofi India

Nehal Vora reappointed MD and CEO of CDSL; SCHIL makes trading debut

Shares of CDSL last closed at Rs 1,382, up 0.25 per cent, valuing the company at Rs 28,879 crore

Nehal Vora reappointed MD and CEO of CDSL; SCHIL makes trading debut
Updated On : 13 Sep 2024 | 11:20 PM IST

Sanofi India stock falls 2% on weak June quarter results; profit falls 16%

The fall in the share price came after the pharmaceutical company reported a weak set of June quarter of financial year 2025 (Q1FY25) results.

Sanofi India stock falls 2% on weak June quarter results; profit falls 16%
Updated On : 29 Jul 2024 | 10:35 AM IST

Sanofi India turns ex-date for healthcare biz demerger; hits 5% upper limit

Each member of Sanofi India holding 1 equity share in Sanofi India as on the Record Date i.e. June 13, 2024 shall entitled to receive 1 equity share of Sanofi Consumer Healthcare India.

Sanofi India turns ex-date for healthcare biz demerger; hits 5% upper limit
Updated On : 13 Jun 2024 | 2:09 PM IST

Stocks to watch on May 14: Shriram Finance, Zomato, DLF, TCS, Maruti Suzuki

Shriram Finance announced that board has approved the sale of its housing finance subsidiary Shriram Housing Finance to Warburg Pincus for Rs 4,630 crore

Stocks to watch on May 14: Shriram Finance, Zomato, DLF, TCS, Maruti Suzuki
Updated On : 14 May 2024 | 8:27 AM IST

Novavax signs Covid-19 license deal with Sanofi, secures business viability

Novavax said it would co-commercialize its Covid-19 vaccine with French drugmaker Sanofi and develop new Covid-19-influenza combination vaccines using Novavax's Matrix-M adjuvant

Novavax signs Covid-19 license deal with Sanofi, secures business viability
Updated On : 10 May 2024 | 3:08 PM IST

Sanofi India introduces diabetes drug 'Soliqua' at Rs 1,850 per pen

Sanofi reported that in India, over 100 million individuals are grappling with type 2 diabetes and its associated complexities

Sanofi India introduces diabetes drug 'Soliqua' at Rs 1,850 per pen
Updated On : 30 Apr 2024 | 5:58 PM IST

Sanofi eyes speedy growth in India, plans fast-tracking of product pipeline

Aiming for a "fair share" in the Indian pharmaceutical market, French drug major Sanofi plans to introduce new drugs and enhance localisation while expanding the reach of its existing brands through collaboration with domestic drug firms, according to a top company official. The company plans to enhance its presence in the diabetes segment and grow its consumer healthcare business after spinning it off into a new entity while also looking at local production of its various best-in-class products in India. In an interaction with PTI, Sanofi India Managing Director Rodolfo Hrosz stated that the company has embarked on a mission to prepare for an accelerated growth path in the country. "We believe we're under-represented (in India) and we see a significant opportunity right now and in the future as well. The potential of this market is phenomenal," he said. He further said: "We are seeking the route to be better represented ... with a fair share of the Indian pharmaceutical ...

Sanofi eyes speedy growth in India, plans fast-tracking of product pipeline
Updated On : 07 Apr 2024 | 12:00 PM IST

Dr Reddy's partners with Sanofi India to distribute vaccine brands in India

Under the terms of this agreement, Dr Reddy's will have exclusive rights to promote and distribute Sanofi's vaccine brands, including Hexaxim, Pentaxim, Tetraxim, Menactra, FluQuadri and Adacel

Dr Reddy's partners with Sanofi India to distribute vaccine brands in India
Updated On : 28 Mar 2024 | 12:23 AM IST

Big plans ahead: Cipla looks for shot in the arm in niche areas

Open to licensing, collaboration in anti-diabetes space

Big plans ahead: Cipla looks for shot in the arm in niche areas
Updated On : 27 Mar 2024 | 10:32 PM IST

Sanofi, Cipla join hands to expand reach of CNS portfolio in India

Cipla will leverage its extensive network to distribute Sanofi's CNS portfolio, including Frisium, a leading anti-epileptic drug

Sanofi, Cipla join hands to expand reach of CNS portfolio in India
Updated On : 26 Mar 2024 | 10:41 PM IST

Sanofi India, Emcure Pharma announce exclusive distribution partnership

Collaboration aligns with Sanofi's growth strategy in India, named 'India for India', aims to accelerate growth across its pharmaceuticals, specialty care, consumer healthcare, and vaccines business

Sanofi India, Emcure Pharma announce exclusive distribution partnership
Updated On : 13 Mar 2024 | 6:44 PM IST

Sanofi loses $21 bn in market value after dropping 2025 profit target

Sanofi shares trade at a 12 month forward price-to-earnings ratio of 11, a discount to AstraZeneca's 16 and global pharma index of 17, according to LSEG data

Sanofi loses $21 bn in market value after dropping 2025 profit target
Updated On : 27 Oct 2023 | 7:48 PM IST

Sanofi India Q2 net profit up 2.5% at Rs 123 cr, revenue at Rs 706 cr

Drug firm Sanofi India on Thursday said its net profit increased by 2.5 per cent to Rs 123 crore for the second quarter ended on June 30, 2023. The company reported a net profit of Rs 120 crore in the April-June quarter of last year. Revenue from operations rose to Rs 706 crore in the period under review from Rs 699 crore in the same period last year, Sanofi India said in a regulatory filing. The company follows a January-December financial year. "The company has delivered a strong second quarter performance despite the National List of Essential Medicines (NLEM) impact," Sanofi India Managing Director Rodolfo Hrosz said. The company will continue to focus on driving further improvement in operating efficiencies while expanding the availability of its established and innovative products in India, he added.

Sanofi India Q2 net profit up 2.5% at Rs 123 cr, revenue at Rs 706 cr
Updated On : 10 Aug 2023 | 6:42 PM IST

No plans to sell stake in consumer healthcare biz: Sanofi India MD Hrosz

'Our insulin portfolio today offers best-in-class insulin for better diabetes management'

No plans to sell stake in consumer healthcare biz: Sanofi India MD Hrosz
Updated On : 12 May 2023 | 7:05 PM IST

Sanofi consumer brands get a shot in the arm on demerger decision

Company says split will allow it to unlock business potential in pharmaceuticals and consumer healthcare

Sanofi consumer brands get a shot in the arm on demerger decision
Updated On : 11 May 2023 | 2:35 PM IST

Stocks to Watch Today: L&T. DRL, Adani Group, Asian Paints, Hero Moto

Stock to Watch today: Adani Enterprises Ltd., the flagship company of Adani Group, said on Wednesday that it will hold a board meeting on May 13 to consider fund raise via issuance of equity

Stocks to Watch Today: L&T. DRL, Adani Group, Asian Paints, Hero Moto
Updated On : 11 May 2023 | 8:06 AM IST

Sanofi consumer brands get a shot in the arm on demerger decision

Sanofi Consumer Healthcare India is expected to be listed on both the BSE and NSE, the company said in an exchange notification

Sanofi consumer brands get a shot in the arm on demerger decision
Updated On : 10 May 2023 | 10:00 PM IST

Fosun's sale of Gland Pharma to become India's biggest pharma deal: Report

With the acquisition, Gland pharma may also get access to global companies like AstraZeneca, Sanofi, Mylan, and Organon

Fosun's sale of Gland Pharma to become India's biggest pharma deal: Report
Updated On : 13 Dec 2022 | 3:22 PM IST

Sanofi India posts Rs 131 cr profit in Sept quarter, revenue at Rs 692 cr

Drug firm Sanofi India on Thursday reported a net profit of Rs 131 crore for the third quarter ended September 2022. The company had posted a net profit of Rs 530 crore in the July-September quarter of last year, the company said in a regulatory filing. The drug firm follows a January-December financial year. Revenue from operations stood at Rs 692 crore in the period under review. The same stood at Rs 754 crore in the corresponding period previous year. The company said the results of the September quarter were not comparable with the same quarter last year as it had transferred its nutraceuticals business to Universal Nutriscience, enabling a gain of Rs 489 crore.

Sanofi India posts Rs 131 cr profit in Sept quarter, revenue at Rs 692 cr
Updated On : 03 Nov 2022 | 9:47 PM IST

Sanofi may underperform in near term; pricing control among key risks

The decline was largely on account of divestment of its nutraceutical business and a few key brands.

Sanofi may underperform in near term; pricing control among key risks
Updated On : 31 Aug 2022 | 10:27 PM IST